`
`PetitionerAmerigenPharmaceuticalsLtd
`
`691.7
`
`$
`
`184.2
`
`$
`
`n/a
`
`n/a
`
`141.5
`
`$
`
`37.7
`
`$
`
`0.540
`
`
`
`0.190
`
`
`
`130.2
`
`$
`
`34.7
`
`$
`
`0.597
`
`
`
`0.210
`
`
`
`128.0
`
`$
`
`34.1
`
`$
`
`0.659
`
`
`
`0.232
`
`
`
`130.4
`
`$
`
`34.7
`
`$
`
`0.729
`
`
`
`0.256
`
`
`
`108.9
`
`$
`
`29.0
`
`$
`
`0.805
`
`
`
`0.283
`
`
`
`52.7
`
`$
`
`14.0
`
`$
`
`0.890
`
`
`
`0.313
`
`
`
`[G]
`
`2008
`
`[F]
`
`1998
`
`[E]
`
`2008
`
`[D]
`
`1998
`
`Present Value of Worldwide Sales
`
`Present Value Factor
`
`Grabowski, Henry and Ronald Hansen, "Briefing Cost of Developing a New Drug," Tufts Center for the Study of Drug Development, 11/18/2014, at 20.
`
`[D] to [E] Calculated from month and day of Toviaz approval (October 31) for 2008 and patent priority (May 12) for 1998.
`
`[B] to [C] = 1 / (CPI for specified year (row) / CPI for specified year (column)) from Exhibit 1049.
`
`The discount rate used is 10.5% based on:
`
`[G] = [A] × [C] × [E].
`
`[F] = [A] × [B] × [D].
`
`[A] Nominal worldwide sales figures are from Exhibit 1036.
`
`Monetary values are in millions of $U.S.
`
`Notes and sources:
`
`n/a
`
`n/a
`
`1,114.0
`
`$
`
`0.909
`
`
`
`0.689
`
`
`
`288.0
`
`$
`
`0.924
`
`
`
`0.700
`
`
`
`236.0
`
`$
`
`0.938
`
`
`
`0.710
`
`
`
`207.0
`
`$
`
`0.957
`
`
`
`0.725
`
`
`
`187.0
`
`$
`
`0.987
`
`
`
`0.748
`
`
`
`137.0
`
`$
`
`1.004
`
`
`
`0.760
`
`
`
`59.0
`
`$
`
`[C]
`
`2008
`
`[B]
`
`1998
`
`Inflation Adjustment
`
`[A]
`
`Sales
`
`Worldwide
`
`Total
`
`2014
`
`2013
`
`2012
`
`2011
`
`2010
`
`2009
`
`Year
`
`Present Value of Toviaz Worldwide Sales